// App-Quantinova.ai

1929 : Analysis of Treatments and Outcomes for Patients with De Novo AML, Therapy-Related AML, and Secondary AML (Prior MDS and CMML) Diagnosed in England between 2011 and 2016 Using Hospital Episode Statistics®

Researchers

Presenter

  • Alex Legg

Principal Investigators

  • Tracey Ellison

  • Matthew O'Connell

  • Mark Evans

Medical Centers

  • Jazz Pharmaceuticals,Oxford,United Kingdom

  • Harvey Walsh,Runcorn,United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Chronic myelomonocytic leukemia

Biomarkers

  • Hematocrit

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Vidaza

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved